In subgroup analyses of EGFR‐ and KRAS‐mutated cases, there was no significant difference in survival between tumours with and without expression of NKX2‐1/TTF‐1 exon 1, although the latter had shorter OS (41 months in EGFR‐mutated cases and 36 months in KRAS‐mutated cases) (see supplementary material, Figure S3). This evidence concerns the gene EGFR and neoplasm.